Dr Nicholas Hardcastle
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
242 Scholarly works
5 Projects
HIGHLIGHTS
2026
Research grants (other domestic)
Evaluating the Effect of Radiotherapy on the Musculoskeletal Growth of Paediatric Patients Using Anatomical Mapping Models
2026
Journal article
Stereotactic Ablative Radiotherapy (SABR) one stop service for lung cancer: A pilot study for early-stage Non-Small-Cell Lung Cancer (NSCLC)
DOI: 10.1016/j.radonc.2026.1115532026
Journal article
Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials
DOI: 10.1016/S1470-2045(26)00170-12026
Journal article
Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study
DOI: 10.1016/S1470-2045(26)00091-42026
Journal article
Deep learning and radiomics models in patients with advanced non-small cell lung cancer treated with immunotherapy combined with stereotactic radiotherapy.
DOI: 10.1038/s41598-026-53520-52024
Research grants (other domestic)
Next-Generation Radiotherapy Treatment Planning With Artificial Intelligence
2022
Research grants (other domestic)
Sitting Up for Radiotherapy
RECENT SCHOLARLY WORKS
2026
Journal article
A novel audit methodology to improve detection of planning and delivery errors in passive motion management
DOI: 10.1016/j.phro.2026.1009762026
Journal article
SABR Versus Radiofrequency Ablation and Cryoablation for Primary Renal Cell Carcinoma: An Economic Evaluation of the FASTRACK II Trial
DOI: 10.1016/j.ijrobp.2025.05.0892026
Journal article
Investigating the Prognostic Value of Pretreatment Body Composition in Women with Ovarian Cancer: Impact on Clinical Outcomes
DOI: 10.3390/cancers180914782026
Journal article
A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiation Therapy in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD)
DOI: 10.1016/j.ijrobp.2025.12.0212026
Journal article
A0342 5-year outcomes of stereotactic radiotherapy for primary renal cell carcinoma from the pooled analysis of the FASTRACK trials
DOI: 10.1016/s0302-2838(26)00398-22026
Journal article
Comparative evaluation of dose accumulation strategies in the clinical reirradiation setting
DOI: 10.1016/j.phro.2026.100954
RECENT PROJECTS
2025
Research grants (ARC, NHMRC, MRFF)
A Registry-Based Randomised Trial of Radiotherapy in Advanced Lung Cancer
2024
Research grants (other domestic)
Stereotactic Ablative Body Radiotherapy (SABR) for 4 Gynaecologic Metastases